Vikki Steel

Tell us about your latest work.

Research in melanoma is constantly evolving; it doesn’t just stop when one question is answered. Each answer leads to new questions and new opportunities to improve outcomes for patients. Over the last decade, results from clinical trials have transformed treatment for Stage III melanoma, with neoadjuvant therapy (treatment where drug therapy is given before surgery) now established as the standard of care. As part of the Investigator Initiated Trials Team, I am currently leading the start-up of the MSLT-3 trial, which takes the next step in exploring this treatment regimen. The study is investigating whether surgery for Stage III melanoma, following neoadjuvant therapy, can be less extensive than the current standard surgery, while still maintaining disease control. If successful, this could mean faster recovery, fewer side effects, and a better quality of life for patients.

How did you get into the melanoma research field?

I’ve always had an interest in cell biology and cancer research. Early in my career, I worked in a laboratory as a Research Assistant before moving into clinical trials, initially focusing on lung and breast cancer while living in the UK. When I moved to Australia, I had the opportunity to work in the melanoma field at a time when effective treatments for advanced patients were very limited. It’s been rewarding to be part of a research area that has made such significant progress over the last decade, and continues to do so.

What has been the highlight of your career so far?

Last year I was fortunate to be able to attend the American Society of Clinical Oncology (ASCO) conference in Chicago, where the NADINA trial was being presented as a plenary (an important session at a conference which is attended by all delegates). This global study demonstrated significant benefits of treating Stage III melanoma patients with neoadjuvant therapy before surgery, rather than proceeding directly to surgery. These results have led to to the recent listing of the combination of ipilimumab and nivolumab on the Pharmaceutical Benefits Scheme here in Australia, which is a great development for Stage III melanoma patients.

Within clinical trials, there are many people that come together to make these a success and it’s a privilege to be a small part of this. Specifically, being at ASCO to see these results shared for the first time with those in the oncology field, and experiencing the knowledge-sharing and networking opportunities, was inspiring and reinvigorated my enthusiasm for my work.

What is your favourite part of your work?

My favourite part of my work is the variety; being involved in multiple clinical trials, each with its own unique tasks and challenges ensures that every day is interesting. I also really appreciate the team I work with; their support and collaboration are a big part of the genuine enjoyment I have for my role and my work.

Do you have a nickname?

My sons call me ‘Miss Beckham’, usually when they want to get me to play soccer with them.

Describe yourself in one word.

Thoughtful.

Do you have a hidden talent?

I’m not sure it should be described as a talent, but it’s definitely something that remains hidden unless I am driving in the car. In the late 90’s, Speed Garage was popular in the UK, this often had MC’ing over the top of heavy basslines and to this day, I can still rap along.

What is your favourite quote?

My favourite quote would be from one of my favourite people, my Nan. She always said that ‘The one thing you can’t stop is time’. A reminder that difficult phases always pass, so to keep going no matter what life may throw at you.

What is your favourite movie?

‘Stand By Me’.

What is a book you’ve enjoyed recently?

‘The Midnight Library’ by Matt Haig.